(2007). A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.
(2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.
(1988). A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens.
(2007). Autoimmune inflammation from the Th17 perspective.
(2008). Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells.
(2010). Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
(2007). Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL10 production.
(2008). Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol 20: 209–214. Role of IFN-b in
(1998). Effect of type I interferon on experimental autoimmune uveoretinitis in rats.
(2009). Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis.
(2008). Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.
(2003). Experimental autoimmune uveoretinitis in the rat and mouse. Curr Protoc Immunol Chapter 15: Unit 15 16. Role of IFN-b in
(2009). IFN-beta inhibits human Th17 cell differentiation.
(2009). IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.
(1998). IL-10 has a protective role in experimental autoimmune uveoretinitis.
(2003). Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis.
(1998). Interferon beta in the treatment of multiple sclerosis: mechanisms of action.
(1999). Interferon beta induces T-helper 2 immune deviation in MS.
(2010). Interferon beta inhibits the Th17 cellmediated autoimmune response in patients with relapsing-remitting multiple sclerosis.
(2007). Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis.
(2010). Interferon-alpha: a therapeutic target in systemic lupus erythematosus.
(2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
(2005). IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.
(2006). Laser acceleration of quasi-monoenergetic MeV ion beams.
(2002). Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis.
(1991). Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications.
(2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
(2009). Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.
(2008). Role of Th1 and Th17 cells in organ-specific autoimmunity.
(2008). Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.
(2009). Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN.
(2010). T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
(2009). T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
(1989). TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
(2002). Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis.
(2008). The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis.
(2005). The effects of interferonbeta on interleukin-10 in multiple sclerosis patients.
(2004). The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells.
(2008). The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.
(2010). Therapy: Behcet uveitis: good results for IFN-alpha-2a.
(1998). Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development.
(2008). Visualization of IFNbeta production by plasmacytoid versus conventional dendritic cells under specific stimulation conditions in vivo.